Last reviewed · How we verify
YF-17D
YF-17D is a live attenuated vaccine.
YF-17D is a live attenuated vaccine. Used for Prevention of yellow fever.
At a glance
| Generic name | YF-17D |
|---|---|
| Sponsor | Takeda |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by inducing a mild infection with a weakened form of the yellow fever virus, which stimulates the immune system to produce antibodies and immune cells that can recognize and fight the virus. This provides long-term immunity against yellow fever.
Approved indications
- Prevention of yellow fever
Common side effects
- Fever
- Headache
- Fatigue
Key clinical trials
- Durability of Vaccine Responses (PHASE4)
- Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination (PHASE4)
- The Immunostimulatory Effects of Gentamicin (PHASE2)
- Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection (PHASE2)
- Yellow Fever Human Infection Model With YF-17D (NA)
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (PHASE2)
- Coadministration of GA2 Sporozoites With Adjuvants (EARLY_PHASE1)
- Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |